<DOC>
	<DOCNO>NCT01472107</DOCNO>
	<brief_summary>The GIMEMA FOUNDATION promote observational ( retrospective ) study number outcome pregnancy childbearing age female patient treat chemotherapy APL . These patient enrol study AIDA0493 , AIDA2000 CR .</brief_summary>
	<brief_title>Study Number Outcome Pregnancy Acute Promielocitic Leukaemia ( APL ) Patients Treated With Chemotherapy</brief_title>
	<detailed_description>Acute promielocitic leukaemia ( APL ) Among AML subtypes , APL distinction curable . The median age diagnosis 40 year , young AML subtypes . The fact APL common young patient increase likelihood may occur fertile age . The introduction ATRA ATO substantially modify outcome APL : two successive study 94 % patient achieve CR 6-yr OS rate ( PETHEMA GIMEMA ) 80 % 2,3,6 . ATRA highly effective APL patient , adverse effect retinoic acid syndrome , arrhythmia , headache , rash , dizziness report . Moreover , retinoids know potent teratogen increase rate spontaneous abortion major fetal abnormality report 10 . Most case report suggest ATRA relatively safe mother fetus use second third trimester . By contrast , use first trim , negative foetal outcome report . No data yet report outcomes pregnancy young patient APL , occur CCR follow ATRA-including chemotherapy regimen . APL therapy AIDA regimen : simultaneous Atra plus IDArubicin ( AIDA ) combination induction treatment , follow 3 course intensive chemotherapy consolidation2 . Consolidation therapy AIDA-0493 trial consist 3 chemotherapy course Ara-C idarubicin3 . Consolidation treatment AIDA-2000 give accord risk-adapted strategy follow : patient low-/intermediate-risk receive 3 consolidation course AIDA-0493 omission cytarabine ; patient high-risk group receive identical 3 cycle AIDA-0493 . Study rationale This observational ( retrospective ) study number outcome pregnancy childbearing age female patient treat chemotherapy APL . These patient enrol study study AIDA0493 , AIDA2000 CR .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<criteria>Patients alive age 18 50 year Patients unequivocal diagnosis APL accord FAB classification WHO 2008 diagnostic criterion . Female childbearing age treat APL , enrol study AIDA0493 , AIDA2000 CR 2 year maintenance exclusion randomize observation AIDA2000 , AIDA0493 Patients age &lt; 18 &gt; 50 year ; Patients receive chemotherapy ; Concomitant psychiatric disorder would interfere prevent subject participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>APL female patient</keyword>
</DOC>